Document |
Document Title |
WO/2024/075760A1 |
The present invention addresses the problem of providing: a novel method for producing a N-acetyl-D-galactosamine ligand-oligonucleotide conjugate, particularly a novel method for producing a N-acetyl-D-galactosamine unit; and a novel in...
|
WO/2024/073809A1 |
The present invention relates to compounds of formula (I) as defined which are biologically active candidates for use in therapy. It also relates to pharmaceutical compositions comprising a compound of formula (I) or formula (II) as defi...
|
WO/2024/065048A1 |
The present disclosure relates to sweetened fibers, compositions thereof, and products comprising the sweetened fiber of the present disclosure, and uses thereof. The present disclosure also relates to methods of preparing the sweetened ...
|
WO/2024/073129A1 |
This disclosure relates generally to inhibitors of MHC-I downmodulation, and methods of treating or preventing an HIV infection by administering the inhibitors to a patient in need of treatment thereof.
|
WO/2024/073673A1 |
The present disclosure provides lipid compounds useful in treating inflammatory skin diseases.
|
WO/2024/064634A1 |
This present invention relates to modified sophorolipid molecules for enhancing the dispersion of particulate substances, including nanoparticles. In certain embodiments, the compositions and methods can be used for improved dispersion i...
|
WO/2024/061271A1 |
Disclosed is a biotinylated heparin pentasaccharide capable of being neutralized, which has a structure as represented by formula (I). The anti-coagulation activity of the biotinylated heparin pentasaccharide capable of being neutralized...
|
WO/2024/062471A1 |
Botanical extracts are provided, which comprise ethanol extracts of Nannochloropsis algae having between 10wt% and 50wt% polar lipids and between 45wt% and 60wt% fatty acids, wherein the fatty acids comprise more than 10wt% of eicosapent...
|
WO/2024/056805A1 |
The present invention relates to new and inventive compounds of formula (I). The compounds are useful as PET (positron emission tomography) tracer.
|
WO/2024/058024A1 |
Provided is a method for producing a glycoside having such a structure that a phenolic compound is bound to the anomeric position in a sugar, the method comprising a step (1) for reacting a peracetylated sugar with a phenolic compound in...
|
WO/2024/053574A1 |
[Problem] The present invention addresses the problem of providing a novel oligosaccharide that is a two-branched glycan that has an α2,6-sialic acid structure at the non-reducing end, a production method for the oligosaccharide, an int...
|
WO/2024/040531A1 |
The invention provides compositions and linking configurations for an oligonucleotide to be conjugated to a carbohydrate ligand for targeted in vivo delivery of an oligonucleotide. These ligand-conjugated compounds target one or more org...
|
WO/2024/036768A1 |
A method for extracting stevioside RD. The method comprises the following steps: providing a solution containing stevioside RD, wherein the pH of the glycoside solution is 5 to 6; at 20-25℃, causing a macroporous neutral adsorption res...
|
WO/2024/036254A2 |
The present invention relates to a process for producing compounds of formula I and/or formula I'. The present invention also relates to a process of selectively cleaving the main ring of a compound of formula IV to provide the starting ...
|
WO/2024/033288A1 |
A compound has the general Formula (I) (e.g., salicin or its derivatives; Compounds 1-7) for use as an inhibitor of SGLT2. A composition comprising the compound (e.g., salicin or its derivatives; Compounds 1-7) and methods for use thereo...
|
WO/2024/012178A1 |
A method for preventing crystalline maltitol from caking during storage, comprising the following steps: performing online real-time detection on the temperature and humidity of dried crystalline maltitol; separately configuring screenin...
|
WO/2024/015844A1 |
The present invention provides modified sophorolipids that can eliminate existing foam and/or prevent the formation of new foam. The modifications including peracetylation and/or global transformation of sophorose hydroxyl groups of soph...
|
WO/2024/010442A1 |
Methods of preparing highly purified steviol glycosides are described. The methods include utilizing enzyme preparations and recombinant microorganisms for converting various starting compositions to target steviol glycosides. The highly...
|
WO/2024/005460A1 |
The present invention provides a compound comprising a self-immolative group and a ligand-drug conjugate comprising same. According to the present invention, an active material may be stably delivered up to a target site, and the active ...
|
WO/2024/005485A1 |
The present disclosure provides a saponin derivative compound, a pharmaceutical composition for preventing or treating coronavirus infection comprising same, and a composition for inhibiting coronavirus entry into cells. A saponin deriva...
|
WO/2023/245821A1 |
Disclosed in the present invention is a preparation method for an N-acetyl-D-galactosamine trimer precursor. With respect to the preparation of the trimer precursor, a preparation method for compound 4 comprises: adding compound 3, a 4Å...
|
WO/2023/248217A1 |
The technology disclosed herein generally concerns detection of enzymes and other biological materials by use of sialylated glycan-based detection units.
|
WO/2023/250439A1 |
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds for inhibiting three prime repair exonuclease 1 ("TREX1").
|
WO/2023/242187A1 |
Methods for the enzymatic modification of saponins produced in plant cell culture, products made thereby, uses of said products and also to other associated aspects. The saponins may be obtained from plant cell culture extracts of Quilla...
|
WO/2023/242338A1 |
The present invention relates to a method for producing acylated derivate of polyphenols comprising α-glucosylation of the phloretin with a sucrose phosphorylase mutant from T. thermosaccharolyticum and acylation with the lipase from Th...
|
WO/2023/245037A1 |
The disclosure provides processes for preparing the compound of formula (VIa-1) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIa-1) are also provided.
|
WO/2023/241571A1 |
The present invention relates to a compound and a use thereof in synthesis of an immunologic adjuvant KRN7000. The compound is KRN7k-9. A method for synthesizing the immunologic adjuvant KRN7000 comprises: (1) synthesizing a saccharide b...
|
WO/2023/232048A1 |
Disclosed are a compound of general formula (I), and a stereoisomer and a cis-trans isomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and R15 are as defined in the present disclosure.
|
WO/2023/100158A9 |
The application relates to fluorescence-quenched substrates of Formula (I) for an acid β-glucosidase (GCase) and their use in a method for determining GCase activity in a cell or tissue, a method for localizing GCase activity within a c...
|
WO/2023/229891A1 |
The present invention includes novel compositions and methods for treating comprising a compound with the Formula I: (I) wherein n 0, 1, 2, 3, 4, or 5; X = NH or O or S; Y = phenyl, or a phenyl group substituted with at least one methyl,...
|
WO/2023/227757A1 |
The invention provides protected ortho-quinone compounds comprising a group represented by: Formula (I) where -Ar- is optionally substituted phenylene, -X is selected from -NH2, -OH and -SH, and the protected forms of each, -W- is option...
|
WO/2023/222730A1 |
The present invention provides a new antibiotic compound termed nidaromycin derived from a new biosynthetic gene cluster (BGC), and its uses. Also provided herein are novel genes and nucleic acid molecules encoding the biosynthetic machi...
|
WO/2023/222986A1 |
The present invention relates to a method for preparing at least one glycolipid according to the following formula (I): [Glc]n-xOy-R (I) [Glc]n representing a linear or branched osidic motif comprising n glucosyl units, where n is betwee...
|
WO/2023/222563A1 |
Alkylpolyglycoside Presently claimed invention is directed to a process for the preparation of an alkylpolyglycoside in the presence of a sulfonated fatty acid as catalyst.
|
WO/2023/222732A1 |
The present invention relates to a novel and efficient method for the production of glycosyl fluorides by the fluorination of a protected saccharide with a fluorinating agent, such as poly(hydrogen fluoride), triethylamine trihydrofluori...
|
WO/2023/222144A1 |
An SGLT2 (sodium glucose transport protein 2) inhibitor having a novel molecular structure, a preparation method therefor, and a use thereof. The SGLT2 inhibitor is a thioglycoside gliflozin analogue; same is designed using C-glycoside a...
|
WO/2023/220174A1 |
This application relates to salts of ascarosides, which can provide various benefits over corresponding ascarosides. For example, certain ascaroside salts can provide beneficial nutrients to a plant to which or near which the salt is app...
|
WO/2023/216732A1 |
Provided is a chemical synthesis method for a helicobacter pylori core lipopolysaccharide oligosaccharide antigen carbohydrate chain, belonging to the field of carbohydrate chemistry. Eight monosaccharide building blocks are prepared by ...
|
WO/2023/213035A1 |
Disclosed is a method for preparing an aryl carbon glycoside compound including a gliflozin drug, belonging to the technical field of pharmaceutical chemistry. According to the present invention, a sulfinate glycosyl donor represented by...
|
WO/2023/214629A1 |
The present invention relates to a composition comprising a pentagalloyl glucose derivative and a phenol compound as active ingredients. The composition according to an aspect not only can be used for anticancer and antidiabetic purposes...
|
WO/2023/213034A1 |
Disclosed are a sulfinate glycosyl donor, a method for preparing same, and use thereof, belonging to the technical field of pharmaceutical chemistry. The present invention particularly provides a sulfinate glycosyl donor represented by f...
|
WO/2023/215306A1 |
Provided herein are improved processes for the preparation of a carbohydrate targeting moiety and its intermediates (I).
|
WO/2023/210233A1 |
The present invention addresses the problem of providing a technique for effectively exerting the activity of a polynucleotide in the brain. The problem is solved by a compound represented by general formula (1) [In the formula, Ms repre...
|
WO/2023/211280A1 |
Provided herein are compounds of formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof: The substituents are as defined herein. Also provided are pharmaceutical compositions comprising the compounds, as well as ...
|
WO/2023/205206A1 |
Provided are compounds useful for the treatment and prevention of infectious diseases. The compound structures are lincosamide analogs modified at the aminooctose (northern) and amino acid (southern) regions. Also provided are methods fo...
|
WO/2023/202034A1 |
The present invention relates to the technical field of biology, and relates to an oligosaccharide fluorescent marker, a preparation method therefor, and use thereof. The preparation method of the present invention comprises the followin...
|
WO/2023/198682A1 |
Compound of the general formula (Ia), (Ib) and (Ic) R50 and R60 are different form each other and are selected from the group consisting of -R70, -ZR70, -Z-OH, -Z-NH2, -Z-SH, -Z-OC(O)R70, -OC(O)R70, - COOH and its corresponding salts, -C...
|
WO/2023/196636A1 |
This application relates to methods of inhibiting the growth of microbes in and/or on plant-based products by treating the plant-based products with a composition including one or more ascarosides.
|
WO/2023/194941A1 |
Methods of preparing N-acetyllactosamine derivatives for use in the preparation 3'-O-glycosyl- and 2',3'-di-O-glycosyl-N-acetyllactosamine derivatives are described. The methods avoid the use of column chromatography and allow for the pr...
|
WO/2023/185505A1 |
A compound of a heparin trisaccharide structure and a preparation method therefor. The compound of the heparin trisaccharide structure has a single optical activity, and the core structure is Glc(1→4)IdoA(1→4)GlcNS. The compound can ...
|